Gapping down
In reaction to disappointing earnings/guidance: NWY -16.3%, VII -12.7%, QSII -9.8%, ROST -6.4%, CLLS -3.6%, CPB -3.1%, DRYS -2.7%, FL -2.6%, BRCD -2.4%, DE -1.8%
M&A news: YHOO -5.2% (suitors are expected to make bids between $2-3 bln for YHOO unit, which was below prior expectations, according to WSJ)
Other news: AXAS -18.8% (commences 25 mln underwritten public offering of common stock), ZIOP -4.2% (following cautious comments from biotech blogger Adam Feuerstein), RDCM -3.6% (prices offering of 1,818,182 ordinary shares at $11.00 per share), BETR -3.1% (prices 10 mln shares of common stock at $11.25 per share), SSS -2.2% (prices 6 mln shares of common stock at $100.00 per share), VRX -0.8% (confirms it has received a notice of default - does not accelerate any of Valeant's indebtedness)
Analyst comments: CMCM -3.7% (downgraded to Underperform from Neutral at Credit Suisse), JNJ -0.7% ( initiated with a Sell at Standpoint Research; tgt $94)
In reaction to disappointing earnings/guidance: NWY -16.3%, VII -12.7%, QSII -9.8%, ROST -6.4%, CLLS -3.6%, CPB -3.1%, DRYS -2.7%, FL -2.6%, BRCD -2.4%, DE -1.8%
M&A news: YHOO -5.2% (suitors are expected to make bids between $2-3 bln for YHOO unit, which was below prior expectations, according to WSJ)
Other news: AXAS -18.8% (commences 25 mln underwritten public offering of common stock), ZIOP -4.2% (following cautious comments from biotech blogger Adam Feuerstein), RDCM -3.6% (prices offering of 1,818,182 ordinary shares at $11.00 per share), BETR -3.1% (prices 10 mln shares of common stock at $11.25 per share), SSS -2.2% (prices 6 mln shares of common stock at $100.00 per share), VRX -0.8% (confirms it has received a notice of default - does not accelerate any of Valeant's indebtedness)
Analyst comments: CMCM -3.7% (downgraded to Underperform from Neutral at Credit Suisse), JNJ -0.7% ( initiated with a Sell at Standpoint Research; tgt $94)